Floatz logo

cd19/cd20 dual-car-t cells

Decitabine-primed Tandem CD19/CD20 CAR T Cells

Han weidongCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Decitabine-primed Tandem CD19/CD20 CAR T Cells cohort.

Asset / SponsorPhaseRating
Zanubrutinib
Curis, Inc.
Phase 2BB
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
PREDNISONE TABLETS
Curis, Inc.
Phase 2BB
Inno-206
Curis, Inc.
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Curis, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

cd19/cd20 dual-car-t cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
56 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
aggressive B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →